Supplementary Table 1. Sever adverse events in RA patients who used targeted therapy for 24 weeks

Category	JAKi (n = 196)		bDMARD (n = 150)	
	Events, n	Patients, n (%)	Events, n	Patients, n (%)
SAE	10	9 (4.6)	6	6 (4.0)
Cardiac arrest	1	1 (0.5)	0	0 (0)
Back pain	1	1 (0.5)	0	0 (0)
Fracture	2	2 (1.0)[a]	0	0 (0)
Enterocolitis	2	2 (1.0)[a]	0	0 (0)
Fever	1	1 (0.5)	0	0 (0)
Avascular necrosis	1	1 (0.5)	0	0 (0)
Gallbladder obstruction	1	1 (0.5)	0	0 (0)
Pneumonia	1	1 (0.5)	1	1 (0.7)
Cubital tunnel syndrome	0	0 (0)	1	1 (0.7)
Nontuberculous mycobacteria aggravation	0	0 (0)	1	1 (0.7)
Acute hepatitis	0	0 (0)	1	1 (0.7)
Myoma of uterus	0	0 (0)	1	1 (0.7)
Mediastinal mass	0	0 (0)	1	1 (0.7)

RA, rheumatoid arthritis; JAKi, Janus kinase inhibitors; bDMARD, biologic disease modifying anti-rheumatic drugs; SAE, severe adverse event.

[a]One patient was reported two events such as fracture and enterocolitis.